Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Globe Newswire 11-May-2026 4:05 PM

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026.

To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call.

About Immunovant 

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit?immunovant.com. 

Contacts: 

Investors 

Keyur Parekh 

keyur.parekh@roivant.com  

Media 

Stephanie Lee 

stephanie.lee@roivant.com